![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Janssen’s Fast-Tracked Nasal Spray Antidepressant Gets FDA Nod
Janssen’s Fast-Tracked Nasal Spray Antidepressant Gets FDA Nod
![Janssen logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/Janssen.gif?t=1607031430&width=430)
March 12, 2019
The FDA approved Johnson & Johnson’s Spravato (esketamine) nasal spray indicated for treatment-resistant depression in conjunction with an oral antidepressant.
The agency approved the drug through its fast-track and breakthrough therapy pathways, based on trial results that established the drug’s safety and efficacy and an endorsement from advisory committees.
The agency required a Risk Evaluation and Mitigation Strategy that restricts distribution to certified doctors’ offices and clinics.
Upcoming Events
-
21Oct